152 related articles for article (PubMed ID: 37962267)
21. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
[TBL] [Abstract][Full Text] [Related]
22. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
[No Abstract] [Full Text] [Related]
23. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
[TBL] [Abstract][Full Text] [Related]
24. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
25. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
26. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
27. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer.
Ke Z; Liu Y; Zhang Y; Li J; Kuang M; Peng S; Liang J; Yu S; Su L; Chen L; Sun C; Li B; Cao J; Lv W; Xiao H
Oncol Rep; 2018 Aug; 40(2):659-668. PubMed ID: 29901149
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
32. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
33. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
34. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
36. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
37. Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian
Shen W; Shan B; Liang S; Zhang J; Yu Y; Zhang Y; Wang G; Bai Y; Qian B; Lu J; Jiang Z
Pathol Oncol Res; 2021; 27():581534. PubMed ID: 34257528
[No Abstract] [Full Text] [Related]
38. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
39. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
